Recall of one lot of Jamp-Atorvastatin Calcium as some bottles may be labelled as containing 10 mg tablets, but contain 40 mg tablets
Is your product affected? Check the DIN and lot number on your package against the list in Health Canada's official notice.
See affected DINs and lot numbers on Health Canada ↗Why it was recalled
Dosage - Labelling
What you should do
- Check your bottle of Jamp-Atorvastatin Calcium, 10 mg tablets to make sure it contains 10 mg tablets and not 40 mg tablets. 10 mg atorvastatin calcium tablets are white to off-white, oval shaped, film-coated tablets, with "10" marked on one side and "AT" marked on the other. 40 mg atorvastatin calcium tablets are white to off-white, oval shaped, film-coated tablets, with "40" marked on one side and "AT" marked on the other. If you are unsure, contact your pharmacist to check if your bottle of Jamp-Atorvastatin Calcium contains the correct tablets. If you see incorrect tablets, stop taking the medication and contact your pharmacy immediately for a replacement product. Return the affected product to your pharmacy for proper disposal. Seek medical attention immediately if you experience any serious adverse effects from atorvastatin calcium which may include muscle pain or muscle weakness.
- Contact Jamp Pharma Corporation by calling toll-free at 1-866-399-9091, extension 501, or by email at serviceclient@jamppharma.com, if you have questions about this recall.
- Report any health product adverse events or complaints to Health Canada.
- Additional information for health care professionals: Health care professionals, such as pharmacists, should check bottles labelled as Jamp-Atorvastatin Calcium, 10 mg tablets before dispensing to ensure they contain the correct tablets.
- Report any unusual packages to the company, and to Health Canada.
Other Recent Recalls
PDP-DIPHENHYDRAMINE
PDP-DIPHENHYDRAMINE 25 MG and 50 MG CAPSULES: Out-of-specification (Impurity)
Type II2026-11-09
Moderate health risk
Unauthorized injectable peptide and non-peptide drugs
Health Canada warns about contaminated unauthorized injectable peptides and non-peptide drugs
2026-11-06
ANTICOAGULANT SODIUM CITRATE SOLUTION, USP
ANTICOAGULANT SODIUM CITRATE SOLUTION, USP 4g/100mL and Potential Bag Leaks
2026-11-03
Recall data is sourced from Health Canada's Recalls and Safety Alerts open dataset. MedShort.ca is an independent tracking tool and does not provide medical advice — for questions about this recall, contact the manufacturer or your pharmacist, or read the full notice linked above.